AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif. –(BUSINESS WIRE)–Aug. 24, 2026– AN2 Therapeutics, Inc.